UC Davis Alzheimer's Disease Research Center
UC Davis Alzheimer's Disease Research Center
批准号:
10666428
负责人:
Charles DeCarli
金额:
$318.85万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-15 至 2026-06-30
关键词:
AccelerationAddressAffectAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAlzheimer&aposs disease riskAreaAutopsyAwarenessBiological MarkersBloodCaregiver researchCaringCharacteristicsChargeClinicalCognitionCognitiveCommunitiesDataDatabase Management SystemsDatabasesDementiaDevelopmentDiagnosisDiseaseDisparityEarly DiagnosisEducational StatusElderlyEnvironmentFosteringFundingFutureGoalsHealth ProfessionalHeterogeneityImageImpaired cognitionIndividualInternationalInterventionInvestigationMeasuresMentorsMethodsMissionOutcomeParticipantPathologicPathologyPersonsPhenotypePopulationPopulation HeterogeneityPreventionPrevention strategyQualifyingResearchResearch ActivityResearch DesignResearch InfrastructureResearch MethodologyResearch PersonnelResearch SupportResourcesRisk FactorsRisk ReductionScanningScienceSecureServicesTechnologyTraining and EducationTranslational ResearchVascular DiseasesVisionWalkingaging brainbrain healthcareercaregivingcohortcollaborative environmentdementia riskdesigndisparity reductioneducation researcheffective therapyepidemiology studyethnic minority populationethnoracialhigh riskimaging biomarkerimprovedinnovationinsightinterdisciplinary collaborationinterestneuropathologynext generationnovelpreventracial minority populationrecruitrisk mitigationstemtherapy developmenttooltraining opportunity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT - Overall
The mission of the UC Davis Alzheimer’s Disease Research Center (UCD ADRC) is to promote a highly
innovative and enriched research environment focused on understanding the heterogeneity of brain aging
among diverse populations that will ultimately lead to effective therapies to prevent or mitigate dementia.
This approach stems from the premise that emphasizing diversity enhances discovery and contributes to
translational science as well as reducing disparities in brain health and care. To accomplish this
mission, the UCD ADRC has developed innovative methods and a unique study design to recruit and retain a
highly demographically diverse clinical and autopsy cohort. All UCD ADRC participants are longitudinally
followed and deeply phenotyped with extensive clinical, blood and imaging biomarker measures as well as
developing state-of-the-art quantitative neuropathology. The UCD ADRC succeeds at these efforts through a
robust research infrastructure, state-of-the-art database management and a highly collaborative environment
consisting of seven well integrated resource cores and one research education component (REC) designed to
facilitate new research efforts and interventions, dissemination of research findings, education and training as
well as encouraging researcher development. Our approach addresses several milestones set by the National
Alzheimer’s Project Act to effectively treat Alzheimer’s disease and associated disorders (ADRD) by 2025.
These include, but are not limited to: 1) M1.L., evaluating disparities among ethnic and racial minority
populations that are at higher risk for AD to mitigate risk and improve cognitive outcomes, 2) M2.H., fully
characterizing mixed pathologies and identifying unique risk factors,3) M5-7., accelerating the development of
treatments that would prevent, halt, or reverse the course of Alzheimer’s disease (AD), 4) M9., improving early
diagnosis through discovery of novel imaging and blood biomarkers, 5) M8., developing novel dementia
prevention strategies, and 6) M13.E.,supporting caregiving through funded caregiver research. The UCD
ADRC also directly supports multiple epidemiological studies of diverse communities through use of research
methods and personnel to gain further insights into dementia risk reduction, early diagnosis, and the impact of
various neuropathologies on aging and dementia.
Our efforts reflect the evolving needs of an increasingly older and more diverse US population, which is
expected to rise to nearly 14 million by midcentury. Moreover, while AD continues to be the major pathological
cause of dementia, more recent studies—including one from the UCD ADRC—find that dementia pathology is
multifactorial and highly heterogeneous, due in part to the co-occurrence of AD and vascular disease, which
varies by ethnoracial characteristics, is emphasized as part of dementia prediction and which can be modified
by treatment even in later life. The UCD ADRC is uniquely qualified to support this research focus with a
considerable impact on future ADRD diagnosis and treatment.
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3390/ijms241210396
发表时间:
2023-06-20
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[]
通讯作者:
Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET.
使用全身 EXPLORER PET 对 18F-florbetaben 进行无创定量。
DOI:
10.21203/rs.3.rs-3764930/v1
发表时间:
2023
期刊:
Research square
影响因子:
--
作者:
[Holy,EmilyN, Li,Elizabeth, Bhattarai,Anjan, Fletcher,Evan, Alfaro,EvelynR, Harvey,DanielleJ, Spencer,BenjaminA, Cherry,SimonR, DeCarli,CharlesS, Fan,AudreyP]
通讯作者:
Fan,AudreyP
DOI:
10.1186/s13063-022-06228-6
发表时间:
2022-05-09
期刊:
Trials
影响因子:
2.5
作者:
[]
通讯作者:
DOI:
10.3390/ijms231810490
发表时间:
2022-09-10
期刊:
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
影响因子:
5.6
作者:
[Kim, Si Eun, Kim, Hee Jin, Jang, Hyemin, Weiner, Michael W., DeCarli, Charles, Na, Duk L., Seo, Sang Won]
通讯作者:
Seo, Sang Won
Cardiovascular health and cognitive outcomes: Findings from a biracial population-based study in the United States.
心血管健康和认知结果:美国一项基于混血人口的研究的结果。
DOI:
10.1002/alz.13421
发表时间:
2023
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
作者:
[Dhana,Anisa, DeCarli,CharlesS, Dhana,Klodian, Desai,Pankaja, Holland,ThomasM, Evans,DenisA, Rajan,KumarB]
通讯作者:
Rajan,KumarB
共 17 条
Do Atmospheric Ultrafine Particles Lodge in the Brain and Cause Cognitive Decline Leading to Alzheimer's Disease Related Dementias?
-
批准号:10591354
-
项目类别:
-
资助金额:$209.43万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's disease
-
批准号:10629449
-
项目类别:
-
资助金额:$576.35万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's disease
-
批准号:10370841
-
项目类别:
-
资助金额:$667.95万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Early and life course socioeconomic adversity and dementia risk in Hispanics/Latinos
-
批准号:10445900
-
项目类别:
-
资助金额:$144.18万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Early and life course socioeconomic adversity and dementia risk in Hispanic/Latinos
-
批准号:10831329
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2022
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10461121
-
项目类别:
-
资助金额:$54.1万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Research Center
-
批准号:10461120
-
项目类别:
-
资助金额:$317.86万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Neuroimaging Core
-
批准号:10461128
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Neuroimaging Core
-
批准号:10666453
-
项目类别:
-
资助金额:$20.75万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10666429
-
项目类别:
-
资助金额:$54.27万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Research Center
-
批准号:10264660
-
项目类别:
-
资助金额:$312.92万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Neuroimaging Core
-
批准号:10264667
-
项目类别:
-
资助金额:$20.36万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10264661
-
项目类别:
-
资助金额:$53.25万
-
财政年份:2021
-
负责人:Charles DeCarli
-
依托单位:
UC Davis Alzheimer's Disease Core Center
-
批准号:10012518
-
项目类别:
-
资助金额:$6.99万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)
-
批准号:10489289
-
项目类别:
-
资助金额:$950.31万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10266150
-
项目类别:
-
资助金额:$881.34万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
Administrative Core
-
批准号:10489290
-
项目类别:
-
资助金额:$342.78万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)
-
批准号:10266149
-
项目类别:
-
资助金额:$1321.22万
-
财政年份:2020
-
负责人:Charles DeCarli
-
依托单位:
Novel imaging and endothelial biomarkers of small vessel cerebrovascular disease
-
批准号:9356355
-
项目类别:
-
资助金额:$101.63万
-
财政年份:2016
-
负责人:Charles DeCarli
-
依托单位:
Novel imaging and endothelial biomarkers of small vessel cerebrovascular disease
-
批准号:9768246
-
项目类别:
-
资助金额:$118.47万
-
财政年份:2016
-
负责人:Charles DeCarli
-
依托单位:
海外基金